Repository logo

Browsing by Author "Brytting, Mia"

Now showing 1 - 10 of 11
  • 2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children
    Publication . Kissling, Esther; Valenciano, Marta; Pozo, Francisco; Vilcu, Ana-Maria; Reuss, Annicka; Rizzo, Caterina; Larrauri, Amparo; Horváth, Judit Krisztina; Brytting, Mia; Domegan, Lisa; Korczyńska, Monika; Meijer, Adam; Machado, Ausenda; Ivanciuc, Alina; Višekruna Vučina, Vesna; van der Werf, Sylvie; Schweiger, Brunhilde; Bella, Antonino; Gherasim, Alin; Ferenczi, Annamária; Zakikhany, Katherina; O Donnell, Joan; Paradowska-Stankiewicz, Iwona; Dijkstra, Frederika; Guiomar, Raquel; Lazar, Mihaela; Kurečić Filipović, Sanja; Johansen, Kari; Moren, Alain; I-MOVE/I-MOVE+ study team
    Background:During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods:We used the test negative design in a multicentre case–control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients ainfluenza Vaccinend a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results: We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0–14, 15–64 and ≥65  years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0–14, 15–64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively. Conclusions: VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65  years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine.
    2018-06Journal article Open access Show more
  • Determinants of fatal outcome in patients admitted to intensive care units with influenza, European Union 2009–2017
    Publication . Penttinen, Pasi; Snacken, René; Lyytikäinen, Outi; Ikonen, Niina; Melillo, Tanya; Melillo, Jackie M.; Staroňová, Edita; Mikas, Ján; Popow-Kraupp, Theresia; Orta Gomes, Carlos M.; Guiomar, Raquel; Slezák, Pavel; Kynčl, Jan; Meijer, Adam; Van Gageldonk-Lafeber, Arianne B.; Domegan, Lisa; O’Donnell, Joan; Lupulescu, Emilia; Popovici, Odette; Carnahan, Annasara; Brytting, Mia; Delgado-Sanz, Concepción; Oliva Domínguez, Jesús A.; Larrauri, Amparo; Hubert, Bruno; Bonmarin, Isabelle; Gomes Dias, Joana; Adlhoch, Cornelia
    Background: Morbidity, severity, and mortality associated with annual influenza epidemics are of public health concern. We analyzed surveillance data on hospitalized laboratory-confirmed influenza cases admitted to intensive care units to identify common determinants for fatal outcome and inform and target public health prevention strategies, including risk communication. Methods: We performed a descriptive analysis and used Poisson regression models with robust variance to estimate the association of age, sex, virus (sub)type, and underlying medical condition with fatal outcome using European Union data from 2009 to 2017. Results: Of 13 368 cases included in the basic dataset, 2806 (21%) were fatal. Age ≥40 years and infection with influenza A virus were associated with fatal outcome. Of 5886 cases with known underlying medical conditions and virus A subtype included in a more detailed analysis, 1349 (23%) were fatal. Influenza virus A(H1N1)pdm09 or A(H3N2) infection, age ≥60 years, cancer, human immunodeficiency virus infection and/or other immune deficiency, and heart, kidney, and liver disease were associated with fatal outcome; the risk of death was lower for patients with chronic lung disease and for pregnant women. Conclusions: This study re-emphasises the importance of preventing influenza in the elderly and tailoring strategies to risk groups with underlying medical conditions.
    2019-10-29Journal article Open access Show more
  • Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
    Publication . Kissling, Esther; Hooiveld, Mariëtte; Martínez-Baz, Iván; Mazagatos, Clara; William, Naoma; Vilcu, Ana-Maria; Kooijman, Marjolein N.; Ilić, Maja; Domegan, Lisa; Machado, Ausenda; de Lusignan, Simon; Lazar, Mihaela; Meijer, Adam; Brytting, Mia; Casado, Itziar; Larrauri, Amparo; Murray, Josephine-L.K.; Behillil, Sylvie; de Gier, Brechje; Mlinarić, Ivan; O’Donnell, Joan; Rodrigues, Ana Paula; Tsang, Ruby; Timnea, Olivia; de Lange, Marit; Riess, Maximilian; Castilla, Jesús; Pozo, Francisco; Hamilton, Mark; Falchi, Alessandra; Knol, Mirjam J.; Kurečić Filipović, Sanja; Dunford, Linda; Guiomar, Raquel; Cogdale, Jade; Cherciu, Carmen; Jansen, Tessa; Enkirch, Theresa; Basile, Luca; Connell, Jeff; Gómez, Verónica; Sandonis Martín, Virginia; Bacci, Sabrina; Rose, Angela M.C.; Pastore Celentano, Lucia; Valenciano, Marta; I-MOVE-COVID-19 and ECDC primary care study teams
    Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
    2022-05-26Journal article Open access Show more
  • Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18)
    Publication . Kissling, Esther; Pozo, Francisco; Buda, Silke; Vilcu, Ana-Maria; Rizzo, Caterina; Gherasim, Alin; Krisztina Horváth, Judit; Brytting, Mia; Domegan, Lisa; Meijer, Adam; Paradowska-Stankiewicz, Iwona; Machado, Ausenda; Višekruna Vučina, Vesna; Lazar, Mihaela; Johansen, Kari; Dürrwald, Ralf; van der Werf, Sylvie; Bella, Antonino; Larrauri, Amparo; Ferenczi, Annamária; Zakikhany, Katherina; O'Donnell, Joan; Dijkstra, Frederika; Bogusz, Joanna; Guiomar, Raquel; Kurečić Filipović, Sanja; Pitigoi, Daniela; Penttinen, Pasi; Valenciano, Marta; Gomez, Veronica; Kislaya, Irina; Nunes, Baltazar; I-MOVE/I-MOVE+ study team
    Introduction: Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. Methods: We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016–17 and 2017–18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group. Results: During the 2017–18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47–69). Among those aged 0–14, 15–64 and ≥65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37–79), 50% (95% CI: 28–66) and 66% (95% CI: 42–80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17–38) in 2016–17 and 13% (95% CI: -15 to 34) in 2017–18. Among 0–14-year-olds VE against A(H3N2) was 28% (95%CI: -10 to 53) and 29% (95% CI: -87 to 73), among 15–64-year-olds 34% (95% CI: 18–46) and 33% (95% CI: -3 to 56) and among those aged ≥65 years 15% (95% CI: -10 to 34) and -9% (95% CI: -74 to 32) in 2016–17 and 2017–18, respectively. Conclusions: Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was <35% in 2016–17 and 2017–18. The egg propagation derived antigenic mismatch of the vaccine seed virus with circulating strains may have contributed to this low effectiveness. A(H3N2) seed viruses for vaccines in subsequent seasons may be subject to the same adaptations; in years with lower than expected VE, recommendations of preventive measures other than vaccination should be given in a timely manner.
    2019-09-17Journal article Open access Show more
  • Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017
    Publication . Valenciano, Marta; Kissling, Esther; Larrauri, Amparo; Nunes, Baltazar; Pitigoi, Daniela; O'Donnell, Joan; Reuss, Annicka; Horváth, Judit Krisztina; Paradowska-Stankiewicz, Iwona; Rizzo, Caterina; Falchi, Alessandra; Daviaud, Isabelle; Brytting, Mia; Meijer, Adam; Kaic, Bernard; Gherasim, Alin; Machado, Ausenda; Ivanciuc, Alina; Domegan, Lisa; Schweiger, Brunhilde; Ferenczi, Annamária; Korczyńska, Monika; Bella, Antonino; Vilcu, Ana-Maria; Mosnier, Anne; Zakikhany, Katherina; de Lange, Marit; Kurečić Filipovićović, Sanja; Johansen, Kari; Moren, Alain; I-MOVE primary care multicentre case-control team
    BACKGROUND: Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent. OBJECTIVES: To explore previous influenza vaccination effects on current season VE among population targeted for vaccination. METHODS: We used 2011/2012 to 2016/2017 I-MOVE primary care multicentre test-negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only. RESULTS: We included 941, 2645 and 959 influenza-like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were -68%, -21% and -19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%). CONCLUSIONS: We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects.
    2018-09Journal article Open access Show more
  • Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort
    Publication . Kissling, Esther; Pozo, Francisco; Buda, Silke; Vilcu, Ana-Maria; Gherasim, Alin; Brytting, Mia; Domegan, Lisa; Gómez, Verónica; Meijer, Adam; Lazar, Mihaela; Vučina, Vesna Višekruna; Dürrwald, Ralf; van der Werf, Sylvie; Larrauri, Amparo; Enkirch, Theresa; O’Donnell, Joan; Guiomar, Raquel; Hooiveld, Mariëtte; Petrović, Goranka; Stoian, Elena; Penttinen, Pasi; Valenciano, Marta; I-MOVE primary care study team
    Introduction: Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim: The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods: We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32–54-year-olds (1964–86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results: Influenza A(H3N2) VE among all ages was −1% (95% confidence interval (CI): −24 to 18) and 46% (95% CI: 8–68), −26% (95% CI: −66 to 4) and 20% (95% CI: −20 to 46) among 0–14, 15–64 and ≥ 65-year-olds, respectively. Among 15–64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: −34 to 50) and −74% (95% CI: −259 to 16), respectively. VE was −18% (95% CI: −140 to 41), −53% (95% CI: −131 to −2) and −12% (95% CI: −74 to 28) among 15–31-year-olds (1987–2003), 32–54-yearolds (1964–86) and 55–64-year-olds (1954–63), respectively. Discussion: The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964–86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15–64-year-olds and the public health impact of the I-REV hypothesis warrant further study.
    2019-11-28Journal article Open access Show more
  • New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic
    Publication . Teirlinck, Anne C.; Johannesen, Caroline K.; Broberg, Eeva K.; Penttinen, Pasi; Campbell, Harry; Nair, Harish; Reeves, Rachel M.; Bøås, Håkon; Brytting, Mia; Cai, Wei; Carnahan, AnnaSara; Casalegno, Jean-Sebastien; Danis, Kostas; De Gascun, Cillian; Ellis, Joanna; Emborg, Hanne-Dorthe; Gijon, Manuel; Guiomar, Raquel; Hirve, Siddhivinayak S.; Jiřincová, Helena; Nohynek, Hanna; Oliva, Jesus Angel; Osei-Yeboah, Richard; Paget, John; Pakarna, Gatis; Pebody, Richard; Presser, Lance; Rapp, Marie; Reiche, Janine; Rodrigues, Ana Paula; Seppälä, Elina; Socan, Maja; Szymanski, Karol; Trebbien, Ramona; Večeřová, Jaromíra; van der Werf, Sylvie; Zambon, Maria; Meijer, Adam; Fischer, Thea K.
    Learning from the COVID-19 pandemic and considering the effects of this pandemic, we provide recommendations that can guide towards sustainable RSV surveillance with the potential to be integrated into the broader perspective of respiratory surveillance.
    2023-04-03Journal article Open access Show more
  • Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018–2019
    Publication . Melidou, Angeliki; Hungnes, Olav; Pereyaslov, Dmitriy; Adlhoch, Cornelia; Segaloff, Hannah; Robesyn, Emmanuel; Penttinen, Pasi; Olsen, Sonja J.; Redlberger-Fritz, Monika; Popow-Kraupp, Therese; Hasibra, Iris; Simaku, Artan; Thomas, Isabelle; Barbezange, Cyril; Dedeić-Ljubović, Amela; Rodić-Vukmir, Nina; Korsun, Neli; Angenova, Svetla; Draženović, Vladimir; Koliou, Maria; Pieridou, Despo; Havlickova, Martina; Nagy, Alexander; Trebbien, Ramona; Galiano, Monica; Thompson, Catherine; Ikonen, Niina; Haveri, Anu; Behillil, Sylvie; Enouf, Vincent; Valette, Martine; Lina, Bruno; Gavashelidze, Mari; Machablishvili, Ann; Gioula, Georgia; Exindari, Maria; Kossyvakis, Athanasios; Mentis, Andreas; Dürrwald, Ralf; Zsuzsanna, Molnar; Monika, Rozsa; Löve, Arthur; Erna, Gudrun; Dunford, Linda; Fitzpatrick, Sarah; Castrucci, Maria Rita; Puzelli, Simona; Sagymbay, Altynay; Nussupbayeva, Gaukhar; Zamjatina, Natalija; Pakarna, Gatis; Griskevičius, Algirdas; Skrickiene, Asta; Fournier, Guillaume; Mossong, Joel; Melillo, Jackie; Zahra, Graziella; Meijer, Adam; Fouchier, Ron; McCaughey, Conall; O'Doherty, Mark; Bragstad, Karoline; Guiomar, Raquel; Pechirra, Pedro; Apostol, Mariana; Alina, Druc; Lazar, Mihaela; Maria, Cherciu Carmen; Komissarov, Andrey; Burtseva, Elena; Gunson, Rory N.; Shepherd, Samantha; Tichá, Elena; Staronova, Edita; Prosenc, Katarina; Berginc, Nataša; Pozo, Francisco; Casas, Inmaculada; Brytting, Mia; Wiman, Åsa; Gonçalves, Ana Rita; Demchyshyna, Iryna; Mironenko, Alla; Moore, Catherine; Cottrell, Simon; European Region influenza surveillance network
    Background: The 2018/2019 influenza season in the WHO European Region was dominated by influenza A (H1N1)pdm09 and (H3N2) viruses, with very few influenza B viruses detected. Methods: Countries in the European Region reported virus characterization data to The European Surveillance System for weeks 40/2018 to 20/2019. These virus antigenic and genetic characterization and haemagglutinin (HA) sequence data were analysed to describe and assess circulating viruses relative to the 2018/2019 vaccine virus components for the northern hemisphere. Results: Thirty countries reported 4776 viruses characterized genetically and 3311 viruses antigenically. All genetically characterized A(H1N1)pdm09 viruses fell in subclade 6B.1A, of which 90% carried the amino acid substitution S183P in the HA gene. Antigenic data indicated that circulating A(H1N1)pdm09 viruses were similar to the 2018/2019 vaccine virus. Genetic data showed that A(H3N2) viruses mostly fell in clade 3C.2a (75%) and 90% of which were subclade 3C.2a1b. A lower proportion fell in clade 3C.3a (23%) and were antigenically distinct from the vaccine virus. All B/Victoria viruses belonged to clade 1A; 30% carried a double amino acid deletion in HA and were genetically and antigenically similar to the vaccine virus component, while 55% carried a triple amino acid deletion or no deletion in HA; these were antigenically distinct from each other and from the vaccine component. All B/Yamagata viruses belonged to clade 3 and were antigenically similar to the virus component in the quadrivalent vaccine for 2018/2019. Conclusions: A simultaneous circulation of genetically and antigenically diverse A(H3N2) and B/Victoria viruses was observed and represented a challenge to vaccine strain selection.
    2020-07-31Journal article Open access Show more
  • Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned
    Publication . Bagaria, Jayshree; Jansen, Tessa; Marques, Diogo F.P.; Hooiveld, Mariette; McMenamin, Jim; de Lusignan, Simon; Vilcu, Ana-Maria; Meijer, Adam; Rodrigues, Ana Paula; Brytting, Mia; Mazagatos, Clara; Cogdale, Jade; van der Werf, Sylvie; Dijkstra, Frederika; Guiomar, Raquel; Enkirch, Theresa; Valenciano, Marta; I-MOVE-COVID-19 study team
    As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March–September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced.
    2022-06-30Journal article Open access Show more
  • Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch
    Publication . O'Toole, Áine; Hill, Verity; Pybus, Oliver G.; Watts, Alexander; Bogoch, Issac I.; Khan, Kamran; Messina, Jane P.; Tegally, Houriiyah; Lessells, Richard R.; Giandhari, Jennifer; Pillay, Sureshnee; Tumedi, Kefentse Arnold; Nyepetsi, Gape; Kebabonye, Malebogo; Matsheka, Maitshwarelo; Mine, Madisa; Tokajian, Sima; Hassan, Hamad; Salloum, Tamara; Merhi, Georgi; Koweyes, Jad; Geoghegan, Jemma L.; de Ligt, Joep; Ren, Xiaoyun; Storey, Matthew; Freed, Nikki E.; Pattabiraman, Chitra; Prasad, Pramada; Desai, Anita S.; Vasanthapuram, Ravi; Schulz, Thomas F.; Steinbrück, Lars; Stadler, Tanja; Parisi, Antonio; Bianco, Angelica; García de Viedma, Darío; Buenestado-Serrano, Sergio; Borges, Vítor; Isidro, Joana; Duarte, Sílvia; Gomes, João Paulo; Zuckerman, Neta S.; Mandelboim, Michal; Mor, Orna; Seemann, Torsten; Arnott, Alicia; Draper, Jenny; Gall, Mailie; Rawlinson, William; Deveson, Ira; Schlebusch, Sanmarié; McMahon, Jamie; Leong, Lex; Lim, Chuan Kok; Chironna, Maria; Loconsole, Daniela; Bal, Antonin; Josset, Laurence; Holmes, Edward; St. George, Kirsten; Lasek-Nesselquist, Erica; Sikkema, Reina S.; Oude Munnink, Bas; Koopmans, Marion; Brytting, Mia; Sudha rani, V.; Pavani, S.; Smura, Teemu; Heim, Albert; Kurkela, Satu; Umair, Massab; Salman, Muhammad; Bartolini, Barbara; Rueca, Martina; Drosten, Christian; Wolff, Thorsten; Silander, Olin; Eggink, Dirk; Reusken, Chantal; Vennema, Harry; Park, Aekyung; Carrington, Christine; Sahadeo, Nikita; Carr, Michael; Gonzalez, Gabo; de Oliveira, Tulio; Faria, Nuno; Rambaut, Andrew; Kraemer, Moritz U.G.
    Late in 2020, two genetically-distinct clusters of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with mutations of biological concern were reported, one in the United Kingdom and one in South Africa. Using a combination of data from routine surveillance, genomic sequencing and international travel we track the international dispersal of lineages B.1.1.7 and B.1.351 (variant 501Y-V2). We account for potential biases in genomic surveillance efforts by including passenger volumes from location of where the lineage was first reported, London and South Africa respectively. Using the software tool grinch (global report investigating novel coronavirus haplotypes), we track the international spread of lineages of concern with automated daily reports, Further, we have built a custom tracking website (cov-lineages.org/global_report.html) which hosts this daily report and will continue to include novel SARS-CoV-2 lineages of concern as they are detected.
    2021-09-17Journal article Open access Show more